CoChat
Sign Up
Cited by 62Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchBone health and treatments

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Open access
Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G. +8 more·2022·Blood Cancer Journal
DOI 10.1038/s41408-022-00695-5PMC PMC9243011
Open this paper in CoChat — free accountOpen PDF

Abstract

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhibitors, monoclonal antibodies, and alkylating agents are the major classes of MM therapies, with several options in each class. Patients who are refractory to one agent in a class may be responsive to a related compound or to a drug from a different class. However, rules for selection of alternative treatments in these situations are somewhat empirical and later phase clinical trials to inform those choices are ongoing. To address these issues the NCI Multiple Myeloma Steering Committee formed a relapsed/refractory working group to review optimal treatment choices, timing, and sequencing and provide recommendations. Additional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41408-022-00695-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treating relapsed/refractory multiple myeloma is increasingly challenging as the evolving frontline landscape complicates second-line treatment selection.

    “Treating relapsed/refractory MM (RRMM) is increasingly challenging1,2 as the evolving frontline landscape complicates second-line treatment selection.”

    From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. [1]Binder M Nandakumar B Rajkumar SV Kapoor P Buadi FK Dingli D Mortality trends in multiple myeloma after the introduction of novel therapies in the United States Leukemia 2021 36 801 10.1038/s41375-021-01453-5 34702976 · DOI
  2. [2]MacEwan JP Majer I Chou JW Panjabi S The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma Ther Adv Hematol 2021 12 20406207211027463 10.1177/20406207211027463 34276923 PMC8255558 · DOI
  3. [3]Corre J Perrot A Hulin C Caillot D Stoppa AM Facon T Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods Leukemia 2021 35 3600 3 10.1038/s41375-021-01250-0 34099876 · DOI
  4. [4]Sneyd MJ Gray AR Morison IM Trends in survival from myeloma, 1990–2015: a competing risks analysis BMC Cancer 2021 21 821 10.1186/s12885-021-08544-7 34271862 PMC8283947 · DOI
  5. [5]Nadeem O Anderson KC The safety of current and emerging therapies for multiple myeloma Expert Opin Drug Saf 2020 19 269 79 10.1080/14740338.2020.1733968 32098519 · DOI
  6. [6]Attal M, Moreau P, Avet-Loiseau H, Harousseau JL. Stem cell transplantation in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007;311–6, American Society of Hematology, Washington, DC. 18024645
  7. [7]Attal M Lauwers-Cances V Hulin C Leleu X Caillot D Escoffre M Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma N Engl J Med 2017 376 1311 20. 10.1056/NEJMoa1611750 28379796 PMC6201242 · DOI · Paper page
  8. [8]McCarthy PL Palumbo A Holstein SA Lauwers-Cances V Petrucci MT Richardson PG A meta-analysis of overall survival in patients with multiple myeloma treated with lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant Haematologica 2016 101 2 3 10.3324/haematol.2015.138149 26721799 PMC4697886 · DOI
  9. [9]Moreau P Kumar SK San Miguel J Davies F Zamagni E Bahlis N Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group Lancet Oncol 2021 22 e105 e18 10.1016/S1470-2045(20)30756-7 33662288 · DOI
  10. [10]Kumar SK Callander NS Adekola K Anderson L Baljevic M Campagnaro E Multiple myeloma, version 3.2021, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2020 18 1685 717 10.6004/jnccn.2020.0057 33285522 · DOI
  11. [11]Moreau P Attal M Hulin C Arnulf B Belhadj K Benboubker L Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Lancet 2019 394 29 38 10.1016/S0140-6736(19)31240-1 31171419 · DOI
  12. [13]Dingli D Ailawadhi S Bergsagel PL Buadi FK Dispenzieri A Fonseca R Therapy for relapsed multiple myeloma: guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy Mayo Clin Proc 2017 92 578 98. 10.1016/j.mayocp.2017.01.003 28291589 PMC5554888 · DOI
  13. [14]Hulin C de la Rubia J Dimopoulos MA Terpos E Katodritou E Hungria V Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice Health Sci Rep 2019 2 e104 10.1002/hsr2.104 30697597 PMC6346989 · DOI
  14. [15]Terpos E Gobbi M Potamianou A Lahaye M Couturier C Cavo M Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: a randomized, controlled, phase III study Eur J Haematol 2018 100 10 9 10.1111/ejh.12937 28801967 · DOI
  15. [16]Stewart AK Rajkumar SV Dimopoulos MA Masszi T Spicka I Oriol A Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 2015 372 142 52. 10.1056/NEJMoa1411321 25482145 · DOI · Paper page
  16. [17]Moreau P Masszi T Grzasko N Bahlis NJ Hansson M Pour L Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma N Engl J Med 2016 374 1621 34. 10.1056/NEJMoa1516282 27119237 · DOI · Paper page
  17. [18]Richardson PG Kumar SK Masszi T Grzasko N Bahlis NJ Hansson M Final overall survival analysis of the TOURMALINE-MM1 Phase III Trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma J Clin Oncol 2021 39 2430 42. 10.1200/JCO.21.00972 34111952 · DOI
  18. [22]Bringhen S Mina R Cafro AM Liberati AM Spada S Belotti A Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study Leukemia 2018 32 1803 7 10.1038/s41375-018-0024-1 29479061 · DOI
  19. [23]Shah JJ Stadtmauer EA Abonour R Cohen AD Bensinger WI Gasparetto C Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma Blood 2015 126 2284 90 10.1182/blood-2015-05-643320 26384354 PMC4643003 · DOI
  20. [24]Dimopoulos M Quach H Mateos MV Landgren O Leleu X Siegel D Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study Lancet 2020 396 186 97 10.1016/S0140-6736(20)30734-0 32682484 · DOI · Paper page
  21. [25]Moreau P Dimopoulos MA Mikhael J Yong K Capra M Facon T Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Lancet 2021 397 2361 71 10.1016/S0140-6736(21)00592-4 34097854 · DOI · Paper page
  22. [26]Attal M Richardson PG Rajkumar SV San-Miguel J Beksac M Spicka I Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Lancet 2019 394 2096 107 10.1016/S0140-6736(19)32556-5 31735560 · DOI
  23. [27]Dimopoulos MA Terpos E Boccadoro M Delimpasi S Beksac M Katodritou E Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Lancet Oncol 2021 22 801 12 10.1016/S1470-2045(21)00128-5 34087126 · DOI · Paper page
  24. [28]Kumar SK Harrison SJ Cavo M de la Rubia J Popat R Gasparetto C Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Lancet Oncol 2020 21 1630 42 10.1016/S1470-2045(20)30525-8 33129376 · DOI
  25. [29]Grosicki S Simonova M Spicka I Pour L Kriachok I Gavriatopoulou M Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Lancet 2020 396 1563 73 10.1016/S0140-6736(20)32292-3 33189178 · DOI
  26. [30]Mateos MV Dimopoulos MA Cavo M Suzuki K Jakubowiak A Knop S Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma N Engl J Med 2018 378 518 28. 10.1056/NEJMoa1714678 29231133 · DOI
  27. [31]Voorhees PM Rodriguez C Reeves B Nathwani N Costa LJ Lutska Y Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN Blood Adv 2021 5 1092 6 10.1182/bloodadvances.2020003642 33606004 PMC7903234 · DOI
  28. [32]Nooka AK Joseph NS Kaufman JL Heffner LT Gupta VA Gleason C Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients Cancer 2019 125 2991 3000 10.1002/cncr.32178 31090928 · DOI
  29. [33]Bahlis NJ Dimopoulos MA White DJ Benboubker L Cook G Leiba M Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Leukemia 2020 34 1875 84 10.1038/s41375-020-0711-6 32001798 PMC7326710 · DOI
  30. [34]Orlowski RZ Moreau P Niesvizky R Ludwig H Oriol A Chng WJ Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups Clin Lymphoma Myeloma Leuk 2019 19 522 30.e1 10.1016/j.clml.2019.04.018 31160237 · DOI
  31. [35]Dimopoulos MA Moreau P Palumbo A Joshua D Pour L Hajek R Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Lancet Oncol 2016 17 27 38 10.1016/S1470-2045(15)00464-7 26671818 · DOI
  32. [36]Richardson PG Laubach JP Munshi NC Anderson KC Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am Soc Hematol Educ Program 2014 2014 255 61 10.1182/asheducation.V2014.1.255.3885263 25696864 · DOI
  33. [37]Kumar SK Lacy MQ Dispenzieri A Buadi FK Hayman SR Dingli D Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma Cancer 2012 118 1585 92 10.1002/cncr.26422 22009602 PMC3262884 · DOI
  34. [38]Goldschmidt H Baertsch MA Schlenzka J Becker N Habermehl C Hielscher T Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE Leukemia 2021 35 1134 44. 10.1038/s41375-020-0948-0 32694619 · DOI
  35. [39]Gonsalves WI Kansagra A Second autologous hematopoietic stem cell transplant as salvage therapy for relapsed multiple myeloma: a global treatment option for eligible patients Acta Haematol 2018 139 45 6 10.1159/000486272 29402801 PMC6524538 · DOI
  36. [40]Giralt S Garderet L Durie B Cook G Gahrton G Bruno B American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma Biol Blood Marrow Transpl 2015 21 2039 51 10.1016/j.bbmt.2015.09.016 PMC4757494 26428082 · DOI
  37. [41]Garderet L Kuhnowski F Berge B Roussel M Escoffre-Barbe M Lafon I Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma Blood 2018 132 2555 63. 10.1182/blood-2018-07-863829 30282798 · DOI
  38. [42]Cook G Ashcroft AJ Cairns DA Williams CD Brown JM Cavenagh JD The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial Lancet Haematol 2016 3 e340 51 10.1016/S2352-3026(16)30049-7 27374467 · DOI
  39. [43]Baertsch MA, Schlenzka J, Christina H, Hielscher T, Raab MS, Hillengass J, et al. Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial ReLApsE suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma. Blood 2018;132:254.
  40. [44]Hagen PA Stiff P The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma Biol Blood Marrow Transpl 2019 25 e98 e107 10.1016/j.bbmt.2018.12.002 30537552 · DOI
  41. [45]Dhakal B D’Souza A Kleman A Chhabra S Mohan M Hari P Salvage second transplantation in relapsed multiple myeloma Leukemia 2021 35 1214 7 10.1038/s41375-020-1005-8 32747684 PMC8020391 · DOI
  42. [46]Shah GBS Rodriguez C Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol Clin Lymphoma Myeloma Leukemia 2021 21 Suppl 2 S158 S159 10.1016/S2152-2650(21)02343-0 · DOI
  43. [47]Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, et al. Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021;13:4706. 10.3390/cancers13184706. PMC8472377 34572934 · DOI
  44. [48]Baz RC Martin TG 3rd Lin HY Zhao X Shain KH Cho HJ Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma Blood 2016 127 2561 8 10.1182/blood-2015-11-682518 26932802 · DOI
  45. [49]Chari A Vogl DT Gavriatopoulou M Nooka AK Yee AJ Huff CA Oral selinexor-dexamethasone for triple-class refractory multiple myeloma N Engl J Med 2019 381 727 38 10.1056/NEJMoa1903455 31433920 · DOI · Paper page
  46. [50]Richard S Jagannath S Targeting nuclear export proteins in multiple myeloma therapy BioDrugs 2022 36 13 25 10.1007/s40259-021-00514-6 35113384 · DOI
  47. [51]Lonial S Lee HC Badros A Trudel S Nooka AK Chari A Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase 2 study Lancet Oncol 2020 21 207 21. 10.1016/S1470-2045(19)30788-0 31859245 · DOI · Paper page
  48. [52]Dimopoulos MA Dytfeld D Grosicki S Moreau P Takezako N Hori M Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma N Engl J Med 2018 379 1811 22. 10.1056/NEJMoa1805762 30403938 · DOI
  49. [53]Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022;28:960–8. 10.1177/10781552211073517. 35006032 · DOI
  50. [54]Lakshman A Kumar SK Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update Am J Hematol 2022 97 99 118 10.1002/ajh.26379 34661922 · DOI
  51. [59]Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, et al. Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma. J Clin Med. 2021;10:4593. 10.3390/jcm10194593. PMC8509238 34640611 · DOI
  52. [60]Cho SF, Xing L, Anderson KC, Tai YT. Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma. Cancers (Basel). 2021;13:6136. 10.3390/cancers13236136. PMC8657018 34885245 · DOI
  53. [61]Costa LJ Davies FE Monohan GP Kovacsovics T Burwick N Jakubowiak A Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma Blood Adv 2021 5 3748 59 10.1182/bloodadvances.2020004146 34470049 PMC8679663 · DOI
  54. [62]Bahlis NJ Baz R Harrison SJ Quach H Ho SJ Vangsted AJ Phase I Study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14) J Clin Oncol 2021 39 3602 12. 10.1200/JCO.21.00443 34388020 PMC8577687 · DOI
  55. [63]Kumar S Kaufman JL Gasparetto C Mikhael J Vij R Pegourie B Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma Blood 2017 130 2401 9 10.1182/blood-2017-06-788786 29018077 · DOI
  56. [64]Chakraborty R Liu HD Rybicki L Tomer J Khouri J Dean RM Progression with clinical features is associated with worse subsequent survival in multiple myeloma Am J Hematol 2019 94 439 45 10.1002/ajh.25415 30663805 · DOI
  57. [65]Rosenberg AS Facon T Parikh K Chung W Srinivasan S Kotey S Association of Morbid progression with overall survival among patients with multiple myeloma: validation of the progression-free survival endpoint Clin Lymphoma Myeloma Leuk 2021 21 345 54.e4 10.1016/j.clml.2020.12.021 33563582 · DOI
  58. [66]Katodritou E Kyrtsonis MC Delimpasi S Kyriakou D Symeonidis A Spanoudakis E Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival Ann Hematol 2018 97 1671 82. 10.1007/s00277-018-3361-2 29756171 PMC6097756 · DOI
  59. [68]Lonial S Jacobus SJ Weiss M Kumar S Orlowski RZ Kaufman JL E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma J Clin Oncol 2019 37 8001 10.1200/JCO.2019.37.15_suppl.8001 PMC7145586 31652094 · DOI · Paper page
  60. [69]Sidana S Tandon N Dispenzieri A Gertz MA Buadi FK Lacy MQ Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse Leukemia 2019 33 730 8 10.1038/s41375-018-0271-1 30323358 · DOI
  61. [70]Tandon N Rajkumar SV LaPlant B Pettinger A Lacy MQ Dispenzieri A Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma Blood Cancer J 2017 7 e528 10.1038/bcj.2017.13 28211889 PMC5386331 · DOI
  62. [71]Peceliunas V Janiulioniene A Matuzeviciene R Zvirblis T Griskevicius L Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma Leuk Lymphoma 2012 53 641 7 10.3109/10428194.2011.627481 21955292 · DOI
  63. [72]Kumar S Mahmood ST Lacy MQ Dispenzieri A Hayman SR Buadi FK Impact of early relapse after auto-SCT for multiple myeloma Bone Marrow Transpl 2008 42 413 20 10.1038/bmt.2008.180 18587435 · DOI
  64. [73]Siegel DS Dimopoulos MA Ludwig H Facon T Goldschmidt H Jakubowiak A Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma J Clin Oncol 2018 36 728 34 10.1200/JCO.2017.76.5032 29341834 · DOI
  65. [74]Oliva S De Paoli L Ruggeri M Caltagirone S Troia R Oddolo D A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma Ann Hematol 2021 100 437 43. 10.1007/s00277-020-04384-w 33392702 · DOI
  66. [75]Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2021;JCO2101935. 10.1200/JCO.21.01935. 34898239 · DOI
  67. [76]Alabanza LM Xiong Y Vu B Webster B Wu D Hu P Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-beta Front Immunol 2022 13 832645 10.3389/fimmu.2022.832645 35222421 PMC8863610 · DOI
  68. [77]Katsarou A Sjostrand M Naik J Mansilla-Soto J Kefala D Kladis G Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence Sci Transl Med 2021 13 eabh1962 10.1126/scitranslmed.abh1962 34878825 PMC9869449 · DOI · Paper page
  69. [78]Chang H Jiang A Qi C Trieu Y Chen C Reece D Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone Leuk Lymphoma 2010 51 2084 91 10.3109/10428194.2010.524325 20929319 · DOI
  70. [79]Walker BA Boyle EM Wardell CP Murison A Begum DB Dahir NM Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma J Clin Oncol 2015 33 3911 20 10.1200/JCO.2014.59.1503 26282654 PMC6485456 · DOI · Paper page
  71. [80]Croft J Ellis S Sherborne AL Sharp K Price A Jenner MW Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial Leukemia 2021 35 2043 53. 10.1038/s41375-020-01096-y 33262523 PMC8257500 · DOI
  72. [81]Kortum KM Mai EK Hanafiah NH Shi CX Zhu YX Bruins L Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes Blood 2016 128 1226 33 10.1182/blood-2016-02-698092 27458004 PMC5524534 · DOI · Paper page
  73. [82]Da Via MC Dietrich O Truger M Arampatzi P Duell J Heidemeier A Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Nat Med 2021 27 616 9 10.1038/s41591-021-01245-5 33619368 · DOI
  74. [83]Samur MK Fulciniti M Aktas Samur A Bazarbachi AH Tai YT Prabhala R Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma Nat Commun 2021 12 868 10.1038/s41467-021-21177-5 33558511 PMC7870932 · DOI
  75. [84]van de Donk N Themeli M Usmani SZ Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma Blood Cancer Disco 2021 2 302 18. 10.1158/2643-3230.BCD-20-0227 PMC8357299 34386775 · DOI
  76. [85]Rajkumar SV Gahrton G Bergsagel PL Approach to the treatment of multiple myeloma: a clash of philosophies Blood 2011 118 3205 11 10.1182/blood-2011-06-297853 21791430 PMC3179390 · DOI
  77. [86]Rajkumar SV Harousseau JL Durie B Anderson KC Dimopoulos M Kyle R Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood 2011 117 4691 5 10.1182/blood-2010-10-299487 21292775 PMC3710442 · DOI · Paper page
  78. [87]Freidlin B Little RF Korn EL Design issues in randomized clinical trials of maintenance therapies J Natl Cancer Inst 2015 107 djv225. 10.1093/jnci/djv225 26286730 PMC4849358 · DOI
  79. [88]Holstein SA Suman VJ McCarthy PL Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep 2019 14 31 8 10.1007/s11899-019-0495-9 30661162 PMC9344397 · DOI
  80. [89]Rajkumar SV Richardson P San Miguel JF Guidelines for determination of the number of prior lines of therapy in multiple myeloma Blood 2015 126 921 2 10.1182/blood-2015-05-647636 26272048 · DOI
  81. [90]Richardson PG San Miguel JF Moreau P Hajek R Dimopoulos MA Laubach JP Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting Blood Cancer J 2018 8 109 10.1038/s41408-018-0141-0 30413684 PMC6226527 · DOI
  82. [91]Fillmore NR Yellapragada SV Ifeorah C Mehta A Cirstea D White PS With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study Blood 2019 133 2615 8 10.1182/blood.2019000406 31003998 PMC6566591 · DOI

Cited by

Sorted by citations

Authors
Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., Lentzsch, S., McCarthy, P. L., Jagannath, S., Yee, A. J., Little, R. F., & Raje, N. S.
Affiliations
  • Mayo Clinic (US)
  • National Institutes of Health (US)
  • University of Wisconsin–Madison (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Roswell Park Comprehensive Cancer Center (US)
  • University of Washington (US)
  • Dana-Farber Cancer Institute (US)
  • Columbia University Irving Medical Center (US)
  • Mount Sinai Hospital (US)
  • Harvard University (US)
Corresponding author
Baizer, Lawrence
ORCID
Venue
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Published
2022-06-29
Volume
12
Issue
6
Pages
98-98
ISSN
2044-5385 (ISSN-L)
DOI
10.1038/s41408-022-00695-5
PMC
PMC9243011
OpenAlex
W4283698909
Cited by
62
References
7
Citations by year
2026: 9 · 2025: 17 · 2024: 21 · 2023: 12 · 2022: 3
FWCI
9.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Blood Cancer Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
relapsed/refractory multiple myeloma, treatment sequencing, salvage therapy, immunomodulators, proteasome inhibitors, monoclonal antibodies, alkylating agents, autologous stem cell transplantation, risk stratification, targeted therapy, clinical trial endpoints, investigational agents, treatment selection
MeSH terms
Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review